anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the titled composition containing phenylenediamine or its derivative and an organic reducing agent, and useful for the analysis by the oxidative color development. CONSTITUTION:The objective stable color-producing reagent composition can be prepared by compounding (A) 1-100mM of phenylenediamine or its derivative (e.g. o-phenylenediamine, 4-amino-N,N-dimethylaniline, etc.), (B) 0.1mM-5M of an organic reducing agent (e.g. an oxalic acid compound, hydroxylamine sulfate, etc.), and if necessary, (C) a peroxidase (e.g. peroxidase, lactoperoxidase, cytochrome peroxidase, etc.), a buffer solution, a standard solution, etc. The contents of individual components of a body fluid can be determined by determining the evolved hydrogen peroxide using said composition. EFFECT:The stability to light can be improved and the non-specific reaction can be suppressed by the use of the organic reducing agent as a component of said composition. The composition is also excellent in the stability of color with time after the color development.
PURPOSE:To enable selective and quantitative adsorption and separation of a drug, its metabolic product and/or an internal standard substance using a specific immobilized antibody column and to enable the simultaneous analysis of a specimen containing multiple components for the clarification of the in vivo kinetics of a drug. CONSTITUTION:Methyl group of a compound having a methyl group adjacent to a double bond and susceptible to oxidative metabolism in vivo (e.g. tolmetin, mefenamic acid and bucumolol) is modified with a protein such as serum albumin or fibrinogen to obtain an antigen. An antibody is prepared from an antiserum produced by injecting the antigen to a rabbit, etc. An immobilized antibody column is produced by using the antibody. A specimen containing the above compound, its metabolic product and/or an internal standard substance is passed through the immobilized antibody column to separate the mixture of the compound, its metabolic product and/or the internal standard substance at the same time and the obtained specimen is analyzed by high-performance liquid chromatography or gas chromatography-mass spectrometry.
<P>PROBLEM TO BE SOLVED: To provide a functional jelly holding minute bubbles of hydrogen inside.  <P>SOLUTION: In this method, water is filled in a container 2 and an ultrasonic vibrating plate 4 is operated while hydrogen is supplied from a hydrogen gas supply pipe 5, and minute bubbles 1b of hydrogen are generated. The minute bubbles 1b have, for example, a diameter of nanosize and are slow in climbing speed in water, therefore, stay in the water for about 10 minutes even if the ultrasonic vibrating plate 4 is stopped. Then, while the minute bubbles 1b stay in the water, a gelling agent is added. When the gelling agent is added, the aqueous solution becomes a jelly 1a and the minute bubbles 1b are uniformly confined inside.  <P>COPYRIGHT: (C)2011,JPO&INPIT
There is an urgent need for effective, safe, and low-cost nonpharmacologic treatments for postoperative pain. This study aims to measure the implementation and effectiveness of Masimo Bridge versus Battlefield Acupuncture (BFA). The Bridge device requires less provider training and delivers treatment for 5 days whereas BFA requires provider training and maintenance of competence, and the duration of effects are unknown. We expect that implementation and effectiveness outcomes will be similar or will favor the Bridge device.

Patients from the Durham Veterans Affairs Medical Center (Durham VAMC) scheduled to undergo total knee arthroplasty (TKA) will be eligible to participate in this study. A sample of 60 veterans will studied over six months. We will offer BFA versus Bridge on alternate months, and recruitment will end when 40 patients have received the Bridge and at least 20 have received BFA.
This invention disclosure provides novel bifunctional antagonistic polypeptides comprising at least one TNF-? binding domain and at least one TGF-? binding domain, which are highly capable of sequestering TNF-? and TGF-? in parallel. Also provided are pharmaceutical compositions of such bifunctional polypeptide antagonists and their uses to treat various complex disease conditions, whose pathogenesis involve the activation of both TNF-?- mediated NF-KB signaling pathway and TGF-?-mediated Smad2/3 signaling pathway.
Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Example systems and methods to visualize and manage medical device operations and troubleshooting are provided. Interface information from a plurality of medical devices is used to generate a visualization of the interface information from the one or more of the plurality of medical devices. Each medical device interface is represented by a miniature representation of the interface in the visualization. Each miniature representation is to convey information shown on the interface of the medical device. The visualization is provided to a user via a user interface at a remote control computer. The user interface is to facilitate user selection of a miniature representation to trigger display of a larger representation of the selected medical device interface information via the user interface.
Carcinogenesis: The carcinogenic potential of TREXIMET has not been studied. 

The carcinogenic potential of sumatriptan was evaluated in oral carcinogenicity studies in mice (78 weeks) and rats (104 weeks). The highest dose administered to mice and rats (160 mg/kg/day) is approximately 9 and 18 times, respectively, the recommended human oral daily dose of 85 mg sumatriptan on a mg/m2 basis. There was no evidence of an increase in tumors in either species related to sumatriptan administration.

The carcinogenic potential of naproxen sodium was evaluated in a 2-year oral carcinogenicity study in rats at doses of 8, 16, and 24 mg/kg/day and in another 2-year oral carcinogenicity study in rats at a dose of 8 mg/kg/day. No evidence of tumorigenicity was found in either study, at doses up to approximately 0.5 times the recommended human oral daily dose of 500 mg/day naproxen sodium on a mg/m2 basis.

Mutagenesis: Sumatriptan and naproxen sodium tested alone and in combination were negative in an in vitro bacterial reverse mutation assay, and in an in vivo micronucleus assay in mice. 

The combination of sumatriptan and naproxen sodium was negative in an in vitro mouse lymphoma tk assay in the presence and absence of metabolic activation. However, in separate in vitro mouse lymphoma tk assays, naproxen sodium alone was reproducibly positive in the presence of metabolic activation.

Naproxen sodium alone and in combination with sumatriptan was positive in an in vitro clastogenicity assay in mammalian cells in the presence and absence of metabolic activation. The clastogenic effect for the combination was reproducible within this assay and was greater than observed with naproxen sodium alone. Sumatriptan alone was negative in these assays.

Chromosomal aberrations were not induced in peripheral blood lymphocytes following 7 days of twice-daily dosing with TREXIMET in human volunteers.

In previous studies, sumatriptan alone was not mutagenic in 2 gene mutation assays (the Ames test and the in vitro Chinese Hamster V79/HGPRT assay) and was not clastogenic in 2 cytogenetics assays (the in vitro human lymphocyte assay and the in vivo rat micronucleus assay).

Impairment of Fertility: The effect of TREXIMET on fertility in animals has not been studied.

In a study in which male and female rats were dosed daily with oral sumatriptan prior to and throughout the mating period, there was a treatment-related decrease in fertility secondary to a decrease in mating in animals treated with 50 and 500 mg/kg/day. The highest no-effect dose for this finding was 5 mg/kg/day, or approximately 0.5 times the recommended human oral daily dose of 85 mg sumatriptan on a mg/m2 basis. It is not clear whether the problem is associated with treatment of the males or females or both combined. In a similar study of sumatriptan by the subcutaneous route there was no evidence of impaired fertility at doses up to 60 mg/kg/day.
Participants will receive trastuzumab + XELOX (Capecitabine + Oxaliplatin) for 3 treatment cycles prior to surgery, each cycle is 3 weeks. Following surgery, participants will receive 5 further cycles of this regimen.
Meclofenamate sodium is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals. The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamate sodium was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro, meclofenamate sodium was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamate sodium. There is no evidence that meclofenamate sodium alters the course of the underlying disease.

In several human isotope studies, meclofenamate sodium, at a dosage of 300 mg/day, produced a fecal blood loss of 1 to 2 mL per day, and 2 to 3 mL per day at 400 mg/day. Aspirin, at a dosage of 3.6 g/day, caused a fecal blood loss of 6 mL per day. 

In a multiple-dose, 1-week study in normal human volunteers, meclofenamate sodium had little or no effect on collagen-induced platelet aggregation, platelet count, or bleeding time. In comparison, aspirin suppressed collagen-induced platelet aggregation and increased bleeding time. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamate sodium.
PROBLEM TO BE SOLVED: To provide a use-time medicine dissolution instrument facilitating injection of a precise quantity of dissolution liquid into a container. SOLUTION: The medicine dissolution instrument comprises a cylindrical guide member 6, a spiked container 7, and a spiked container storing member 8. The inner diameter of the guide member 6 is almost same as the outer diameter of a rubber plug part 4 for air-tightly sealing an opening 3h of a medicine storage container 3 for storing a medicine M, and a screw part 6n1 is formed on the periphery of the guide member 6. The spiked container 7 has a dissolution liquid storage container 7 with an opening part 7ha for containing a dissolution liquid L whose quantity is previously set and spike needles 7b attached air-tightly to the opening part 7ha of the dissolution liquid storage container 7.  The spiked container storing member 8 has screw parts 8n, to be engaged with the screw part 6n1 formed on the periphery of the guide member 6, between one end and the other end on the inner surface for storing the spiked container 7. The spiked container 7 is stored in the spiked container storing member 8, with the spike needles 7b facing to one end of the guide member 6.
High-density lipoprotein (HDL) is known to have a protective role in cardiovascular disease. Apart from transporting cholesterol from peripheral blood vessels back to the liver where it is processed, HDL has the ability to inhibit chemical changes (called oxidation) to low-density lipoprotein (LDL) which would make the latter more toxic to the body. HDL can also stop inflammatory particles from damaging the vessel walls. The anti-oxidation and anti-inflammatory properties of HDL are associated with an enzyme on HDL called paraoxonase 1 (PON1). It is not the level of measured HDL but the level of PON1 activity that is important in preventing cardiovascular disease. PON1 activity determines the quality of HDL and the effect against vascular disease.

Obese patients accumulate most of the fat within their abdomen (termed visceral fat). It is known that visceral fat produces large quantities of inflammatory particles so that obese patients have increased systemic inflammation and thus higher risk of vascular disease. The impact of heightened inflammatory status on HDL functions and PON1 activity is not known. Weight-reducing (bariatric) surgery can result in significant weight loss in obese patients. It is unclear whether the weight loss is associated with improvement in HDL functions, possible reversal of lipoprotein abnormalities and other physiological parameters. We plan to study a population of obese patients scheduled to have bariatric surgery before and after the surgery and compare the results with a matching population of healthy control patients.

Diabetic patients are at increased risk of developing cardiovascular disease. HDL in diabetic patients is often dysfunctional. Even though HDL levels are normal, PON1 activity may be reduced. LDL is able to interact with raised levels of blood glucose (called glycation) and become more harmful to the body. Glycation of lipoproteins associated with PON1 may affect PON1 activity. We plan to study glycated lipoproteins and PON1 activity in a population of diabetic patients who have either type 1 or type 2 diabetes. Some of the type 1 diabetics will have diabetic kidney disease, these patients are known to be particularly at high risk of cardiovascular complications. We also plan to recruit a cohort of patients who do not have diabetes but who have had an abnormal blood glucose test. These patients will be having an oral glucose tolerance test (OGTT) which establishes whether they have diabetes. During the OGTT, patients are given an oral glucose load which results in a rapid rise in blood glucose. We will see if this accelerated change in blood glucose level has any effects on the glycation of lipoproteins.
The invention discloses an application of Chukrasone B in preparation of anti-diabetic medicines. The invention provides a brand new selection and concept to existing anti-diabetic medicines, expands the selective field of anti-diabetic medicines and further makes contribution to development of the technical field. The application of Chukrasone B disclosed by the invention is proved to have a remarkable anti-diabetic effect. A compound with a definite chemical structure is used by the invention. The application of the Chukrasone B in preparation of anti-diabetic medicines is disclosed for the first time. As the framework type is a brand new framework type and the activity of the Chukrasone B in prevention and treatment of diabetes is unimaginably strong, the probability of giving any enlightenment by other compounds does not exist. The Chukrasone B has remarkable substantial characteristics and meanwhile has remarkable progress in treatment of diabetes.
OBJECTIVES: To summarize the clinical features of pediatric femoral neck fractures and analyze the risk factors for avascular necrosis of the femoral head.
METHODS: A retrospective analysis of the case data of pediatric femoral neck fractures treated in our hospital from January 2010 to December 2022, including gender, age, fracture type, causative factors, and surgical details. The occurrence of avascular necrosis of the femoral head was recorded and risk factors were analyzed.
RESULTS: From January 2010 to December 2022, a total of 45 cases of femoral neck fractures were treated in our hospital with a median age at onset of 93 months (IQR=81) and a median time from injury to surgery of 96 hours (IQR=46). Closed reduction was performed in 36 cases, while open reduction was performed in 9 cases. Avascular necrosis of the femoral head occurred in 29 cases postoperatively, while it did not occur in 16 cases. Increased time from injury to surgery and greater degree of fracture displacement were independent risk factors for avascular necrosis of the femoral head. The risk of avascular necrosis in Garden IV type femoral neck fractures was significantly higher than in Garden II and III type patients. An injury-to-surgery time exceeding 82.5 hours was identified as a critical threshold for the development of avascular necrosis of the femoral head.
CONCLUSION: Pediatric femoral neck fractures have a low incidence rate and are mostly caused by high-energy trauma, often resulting in severe injuries. Therefore, actively maintaining stable vital signs and properly managing associated injuries, timely surgical intervention for femoral neck fractures, achieving good reduction and fixation of displaced fractures are crucial in the treatment of pediatric femoral neck fractures.
FIELD: medicine, oncology. SUBSTANCE: it is suggested to conduct either before and/or after neurosurgical interference immunotherapy dealing with intravenous injection of lymphakine-activated killer cells isolated from 800 ml patient's venous blood with 2 mln. IU yeast recombinant interleukin-2. The present method enables to provide easy surgical removal of tumor at no pronounced side effects. EFFECT: higher efficiency of therapy. 1 cl, 6 ex
Approximately 400 healthy, ambulatory adults ages 65-80 will be randomized into one of four study groups to receive a single immunization of a licensed trivalent inactivated influenza vaccine or one of three dose levels of an investigatioanl trivalent recombinant influenza HA protein vaccine. The study will be conducted in 2 stages. In the first stage, 80 subjects will be randomized (20 per group) and receive one vaccination on Day 0. Safety will be evaluated after Stage 1 subjects have completed a 7 day follow-up. Enrollment of Stage 2 subjects will begin after the safety data for Stage 1 has been reviewed. In Stage 2, 320 subjects will be randomized (80 per group) and receive one vaccination on Day 0. Blood and nasal secretions will be collected prior to an approximately one month after vaccination to assess antibody responses.
Right portal vein embolization including segment 4 portal vein branches. All patients subjected to selective right portal vein embolization including segment 4 portal vein branches prior to planned hepatobiliary surgery.
BACKGROUND: Body weight loss (BWL) after gastrectomy impact on the short- and long-term outcomes. Oral nutritional supplement (ONS) has potential to prevent BWL in patients after gastrectomy. However, there is no consistent evidence supporting the beneficial effects of ONS on BWL, muscle strength and health-related quality of life (HRQoL). This study aimed to evaluate the effects of ONS formulated primarily with carbohydrate and protein on BWL, muscle strength, and HRQoL.
METHODS: This will be a multicenter, open-label, parallel, randomized controlled trial in patients with gastric cancer who will undergo gastrectomy. A total of 120 patients who will undergo gastrectomy will be randomly assigned to the ONS group or usual care (control) group in a 1:1 ratio. The stratification factors will be the clinical stage (I or ≥ II) and surgical procedures (total gastrectomy or other procedure). In the ONS group, the patients will receive 400 kcal (400 ml)/day of ONS from postoperative day 5 to 7, and the intervention will continue postoperatively for 8 weeks. The control group patients will be given a regular diet. The primary outcome will be the percentage of BWL (%BWL) from baseline to 8 weeks postoperatively. The secondary outcomes will be muscle strength (handgrip strength), HRQoL (EORTC QLQ-C30, QLQ-OG25, EQ-5D-5L), nutritional status (hemoglobin, lymphocyte count, albumin), and dietary intake. All analyses will be performed on an intention-to-treat basis.
DISCUSSION: This study will provide evidence showing whether or not ONS with simple nutritional ingredients can improve patient adherence and HRQoL by reducing BWL after gastrectomy. If supported by the study results, nutritional support with simple nutrients will be recommended to patients after gastrectomy for gastric cancer.
TRIAL REGISTRATION: jRCTs051230012; Japan Registry of Clinical Trails. Registered on Apr. 13, 2023.
This is a prospective, randomized, double-blind cohort study conducted from May 2023 to April 2024. The study aims to evaluate the effectiveness of a non-human contact gaze tilt test in the diagnosis of children with superior oblique Muscle Palsy. Patients who met the inclusion criteria for outpatient and inpatient ophthalmic surgery for strabismus and pediatric ophthalmology were enrolled after signing a written informed consent. The gaze tilt test was added to the normal treatment process and performed by a professional ophthalmologist who was not involved in the treatment process. The test involved playing a small animated video with a visual mobile device at a distance of 33 cm and 3 m, respectively, to determine the optimal angle of head position improvement and the spatial tilt angle of the screen relative to the orthostatic position. A third-party analysis of the data was performed to identify myotonic and oculocutaneous tilts and compared with the results of the conventional test. The study aims to clarify the authenticity, reliability, and practicality of the gaze object tilt test in diagnosing and treating oculocutaneous squint.
PURPOSE:To obtain gum having extremely excellent cleaning function in the mouth, capable of supplying nutrients of powder and essence containing calcium, chloroplast such as green tea, pine or bamboo, vitamin, etc. CONSTITUTION:Powder 1 prepared by adjusting calcium such as bone or shell to a proper particle size is blended with a main body of gum 2. Further the blend is optionally mixed with fine powder or essence 3 of chloroplast such as green tea, pine or bamboo. sordes 5 or other attached materials stuck to the surface of a tooth 4 are removed by abrading action of the calcium powder 1 blended with the main body of gum 2 to clean the interior of mouth. The particles 1 of calcium are separated from the gum with chewing the gum, swallowed and absorbed in body. In the case of the gum blended with the fine powder and essence 3 of chloroplast such as green tea, pine or bamboo, the interior of mouth is kept clean by anti-oxidant action and detoxication of the fine powder or essence 3 and the fine powder and essence are absorbed with the particles 1 of calcium to raise activity of body.
Botulism toxin A dosage was based on plan developed in clinical setting with study PI and physical therapist. Drug was dosed in 25 cc syringe,diluted with normal saline and injections occured based on treatment plan.
Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available, then patients must agree to submit a post-mortem biopsy specimen.
PCT No. PCT/DE91/00562 Sec. 371 Date Jun. 1, 1993 Sec. 102(e) Date Jun. 1, 1993 PCT Filed Jul. 5, 1991 PCT Pub. No. WO92/00991 PCT Pub. Date Jan. 23, 1992.The unsaturated 17 alpha -cyanomethyl-17 beta -hydroxy steroids of the formula I,    <IMAGE>   in which R1=Me, Eth; R2=H, Me; R3=H, OH, an acetoxy or alkoxy group; R4=H, R5=OH, an acetoxy, alkoxy group of R4 and R5 together represent a keto- or ketal group and double bonds are contained in the basic structure of the steroid, particularly between the 15 and 16 position in the steroid ring, from unsaturated 17-ketosteroids of the general formula II as described herein with the aforementioned meanings of R1 to R5 by reacting the unsaturated 17-ketosteroids with LiCH2CN and subsequently hydrolyzing. The compounds of formula I are pharmacologically interesting steroid compounds or also intermediate products for the synthesis of highly-effective steroid products which can be used in human and veterinary medicine for the treatment of endocrine disorders and for reproductive control based on their specific hormonal/anti-hormonal actions. The compounds are suitable for the treatment of endometriosis and also in combination with preparations with ethinylestradiol for fertility control.